Dimerix Ltd has released a press release.
Dimerix Phase 2a Subgroup Analysis Results
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Dimerix
- Ethics Committee Approval for Pharmacokinetic Trial
- Dimerix Receives $545k R&D Tax Refund
- Notice of Annual General Meeting/Proxy Form
- DMX-200 tablet manufacture and human study timeline
- Positive Results from Phase 2a Trial of DMX-200
Later from Dimerix
- Suspension from Official Quotation
- Entitlement Offer to raise $5.5 million
- Entitlement Offer Booklet
- Proteomics partnership to improve treatment of CKD
- DMX-200 Dosage Optimisation Study Successfully Completed
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix